On March 28, 2023, Evercore ISI Group initiated coverage of Astria Therapeutics with a Outperform recommendation.
Analyst Price Forecast Suggests 114.24% Upside
As of March 27, 2023, the average one-year price target for Astria Therapeutics is $26.18. The forecasts range from a low of $20.20 to a high of $33.60. The average price target represents an increase of 114.24% from its latest reported closing price of $12.22.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Astria Therapeutics is $0MM, a decrease of 100.00%. The projected annual non-GAAP EPS is -$2.99.
What are Large Shareholders Doing?
Perceptive Advisors holds 2,189K shares representing 7.82% ownership of the company. In it's prior filing, the firm reported owning 1,281K shares, representing an increase of 41.48%. The firm increased its portfolio allocation in ATXS by 172.35% over the last quarter.
Fairmount Funds Management holds 1,901K shares representing 6.79% ownership of the company. In it's prior filing, the firm reported owning 912K shares, representing an increase of 52.05%. The firm increased its portfolio allocation in ATXS by 210.01% over the last quarter.
Deep Track Capital holds 1,817K shares representing 6.49% ownership of the company.
Vivo Capital holds 1,681K shares representing 6.01% ownership of the company. In it's prior filing, the firm reported owning 1,000K shares, representing an increase of 40.52%. The firm increased its portfolio allocation in ATXS by 188.79% over the last quarter.
Cormorant Asset Management holds 1,650K shares representing 5.90% ownership of the company. In it's prior filing, the firm reported owning 1,200K shares, representing an increase of 27.27%. The firm increased its portfolio allocation in ATXS by 116.82% over the last quarter.
What is the Fund Sentiment?
There are 93 funds or institutions reporting positions in Astria Therapeutics. This is an increase of 22 owner(s) or 30.99% in the last quarter. Average portfolio weight of all funds dedicated to ATXS is 0.47%, an increase of 181.06%. Total shares owned by institutions increased in the last three months by 124.22% to 22,204K shares. The put/call ratio of ATXS is 0.69, indicating a bullish outlook.
Astria Therapeutics Background Information
(This description is provided by the company.)
Astria Therapeutics’ dedicated and passionate team is devoted to bringing life-changing therapies to patients and families impacted by HAE and rare and niche allergic and immunological diseases.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
